Theriva Biologics Files Q1 2025 10-Q
Ticker: TOVX · Form: 10-Q · Filed: May 14, 2025 · CIK: 894158
| Field | Detail |
|---|---|
| Company | Theriva Biologics, Inc. (TOVX) |
| Form Type | 10-Q |
| Filed Date | May 14, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, preferred-stock, common-stock
Related Tickers: TMBX
TL;DR
Theriva Biologics (TMBX) filed its Q1 2025 10-Q, showing preferred stock and common stock details.
AI Summary
Theriva Biologics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Synthetic Biologics, Inc., reported financial data for its fiscal year ending December 31, 2025, with a Q1 filing. Key financial elements include Series C and Series D Convertible Preferred Stock and Common Stock, with activity noted in Additional Paid-In Capital for the 2024 fiscal year.
Why It Matters
This filing provides investors with an update on Theriva Biologics' financial position and operational activities for the first quarter of 2025, crucial for understanding the company's ongoing performance and future prospects.
Risk Assessment
Risk Level: medium — As a biopharmaceutical company, Theriva Biologics faces inherent risks related to drug development, regulatory approvals, and market competition, which are typical for the industry.
Key Numbers
- Q1 2025 — Reporting Period (First quarter of the 2025 fiscal year)
- 2024 — Fiscal Year (Period for which Additional Paid-In Capital activity is noted)
Key Players & Entities
- Theriva Biologics, Inc. (company) — Filer of the 10-Q
- Synthetic Biologics, Inc. (company) — Former name of Theriva Biologics, Inc.
- March 31, 2025 (date) — End of the reporting period
- December 31, 2025 (date) — Fiscal year end
- Series C Convertible Preferred Stock (security) — Financial instrument mentioned
- Series D Convertible Preferred Stock (security) — Financial instrument mentioned
FAQ
What is the primary business of Theriva Biologics, Inc.?
Theriva Biologics, Inc. is in the Pharmaceutical Preparations industry, SIC code 2834.
When was Theriva Biologics, Inc. previously known by another name?
Theriva Biologics, Inc. was formerly known as Synthetic Biologics, Inc., with a name change date of March 5, 2012.
What is the fiscal year end for Theriva Biologics, Inc.?
The fiscal year end for Theriva Biologics, Inc. is December 31.
What specific financial instruments are mentioned in relation to the 2024 fiscal year?
The filing mentions Series C Convertible Preferred Stock, Series D Convertible Preferred Stock, and Common Stock, with activity in Additional Paid-In Capital for the 2024 fiscal year.
What is the business address of Theriva Biologics, Inc.?
The business address is 9605 Medical Center Drive, Suite 270, Rockville, MD 20850.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding Theriva Biologics, Inc. (TOVX).